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Abstract
Background: Heterozygous mutations in COL2A1 create a spectrum of clinical entities called type II collagenopathies
that range from in utero lethal to relatively mild conditions which become apparent only during adulthood. We aimed
to characterize the clinical, radiological, and molecular features of a family with an atypical type II collagenopathy.
Case presentation: A family with three affected males in three generations was described. Prominent clinical findings
included short stature with platyspondyly, flat midface and Pierre Robin sequence, severe dysplasia of the proximal
femora, and severe retinopathy that could lead to blindness. By whole exome sequencing, a novel heterozygous
deletion, c.4161_4165del, in COL2A1 was identified. The phenotype is atypical for those described for mutations in the
C-propeptide region of COL2A1.
Conclusions: We have described an atypical type II collagenopathy caused by a novel out-of-frame deletion in the
C-propeptide region of COL2A1. Of all the reported truncating mutations in the C-propeptide region that result in
short-stature type II collagenopathies, this mutation is the farthest from the C-terminal of COL2A1.
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Background
Patients with COL2A1 mutations are collectively called
type II collagenopathies. Missense mutations or in-frame
derangement in the triple-helical region cause a phenotype
on the spondyloepiphyseal dysplasia (SED) spectrum from
lethal SED including achondrogenesis type II (ACG2;
OMIM# 200610) and hypochodrogenesis through spondy-
loepiphyseal dysplasia congenita (SEDC; OMIM#183900),
while mutations in the triple helical or N-propeptide re-
gions cause Stickler syndrome type I (STL1; OMIM#
108300) or Kniest dysplasia (OMIM# 156550) [1]. Unlike
mutations in the triple-helical or N-propeptide regions,
those in the C-propeptide region generally produce atypical
phenotypes such as platyspondylic lethal skeletal dysplasia,
Torrance type (PLSDT# OMIM 151210) [2], spondyloper-
ipheral dysplasia (SPPD) (OMIM# 271700) [3], vitreoreti-
nopathy with phalangeal epiphyseal dysplasia (VPED) [4],
avascular necrosis of the femoral head (ANFH; OMIM#
608805) [5], or early-onset osteoarthritis (OA) [6]. Here, we
describe a family with atypical features of type II collageno-
pathies caused by a novel mutation in COL2A1. As far as
we know, this truncating mutation in the C-propeptide re-
gion is the farthest one from the 3’ end of the gene that
causes a disease with short stature, suggesting the existence
of the mutant protein.
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We studied a Thai family with skeletal dysplasia who
attended the Genetics Clinic at the King Chulalongkorn
Memorial Hospital, Bangkok, Thailand. The medical
data, pedigree, physical examinations, and laboratory re-
sults were recorded. The written informed consent and
parental consent (for the proband) was obtained after
explanation of the possible consequences of this study.
Genomic DNA preparation and whole-exome sequencing
To perform genetic analysis, genomic DNA was isolated
from peripheral blood leukocytes using a Puregene Blood
kit (Qiagen, Hilden, Germany). The genomic DNA was
sent to Macrogen, Inc. (Seoul, South Korea) for whole-
exome sequencing (WES). DNA was captured using a
SureSelect Human All Exon version 4 kit (Agilent Tech-
nologies, Santa Clara, CA) and sequenced on a Hiseq2000
instrument. Base calling was performed and quality scores
were analyzed using Real Time Analysis software version
1.7. Sequence reads were aligned against the University of
California Santa Cruz human genome assembly hg19
using Burrows-Wheeler Alignment software (bio-bwa.-
sourceforge.net/). Single-nucleotide variants (SNVs) and
insertions/deletions (Indels) were detected by SAM-
TOOLS (samtools.sourceforge.net/) and annotated against
dbSNP & the 1000 Genomes Project. After quality filter-
ing, we looked for variants located in the coding regions
of known skeletal dysplasia genes for all potential patho-
genic SNVs and Indels. Variant calling exclusion criteria
were (a) coverage <10×; (b) quality score <20; (c) minor al-
lele frequency ≥1% in the 1000 Genomes Project; and (d)
non-coding variants and synonymous exonic variants. The
remaining variants were subsequently filtered out if they
were present in our in-house database of 165 unrelated
Thai exomes. The variants were confirmed by PCR and
Sanger sequencing.
Existing SNVs or known pathogenic mutations were
filtered out using the Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk/ac/index.php) and the Exome
Aggregation Consortium database (exac.broadinstitute.org).
Results
A 20 month-old male (IV:3; Fig. 1) is the first child of a
non-consanguineous couple. His mother had miscarriages
in the first trimester of the two previous pregnancies. The
causes of both miscarriages were unknown. He was born
at term by normal delivery with a birth weight of 2,850 g
(10th centile) and a length of 45 cm (<3rdcentile, −4 SD).
Physical examination revealed short stature, flattened face,
cleft palate, micrognathia, short neck, and umbilical hernia
(Fig. 2a). A radiograph obtained at age 20 months showed
oval-shaped vertebral bodies (Fig. 2b). Ossification of the
femoral head was absent. Long bones showed short broad
tubular shape with metaphyseal flaring (Fig. 2c). Other os-
sification centers appeared age-appropriate (Fig. 2c and d).
Hands and feet radiographs were normal (Fig. 2e and f).
His eyes examination and audiometry showed no abnor-
mality. He was given a clinical diagnosis of SEDC.
The proband’s father (III:1; Fig. 1) is a 26 year-old
man. He had short trunk dwarfism with a height of
125 cm (−9 SD). He had a barrel-shaped chest, hyperlor-
dosis of the lumbar spine, and flexion contracture of
both hips (Fig. 3a). Hands and feet, including radio-
graphs, were apparently normal (Fig. 3b and c). A radio-
graph of the thoracolumbar spine showed flattened
vertebral bodies with kyphotic deformity (Fig. 3d). Se-
vere dysplasia of the bilateral proximal femoral epiphyses
and hip dislocation were observed (Fig. 3e). Generalized
osteopenia was noted. He was blind in the left eye since
he was 8 years old, while his right eye had severe myopia
and retinal detachment. He also had umbilical hernia
when he was young but it spontaneously resolved.
The proband’s grandfather (II:3; Fig. 1) had short stat-
ure (−8 SD). He also had a barrel-shaped chest, hyper-
lordosis of the lumbar spine and flexion contracture of
both hips. A radiograph of the thoracolumbar spine and
pelvis showed flattened vertebral bodies, severe dysplasia
of the bilateral proximal femoral epiphysis and hip dis-
location (Fig. 3f ). His hands and feet were normal. His
eyes were reported normal but had never been formally
evaluated. He died at the age of 54 because of septicemia
after a nephrostomy as treatment for obstructive uropa-
thy from ureteric stones. A blood sample was not avail-
able for mutation analysis.
Whole-exome sequencing (WES) of the proband revealed
a five-nucleotide out-of-frame deletion (NM_001844.4:
c.4161_4165del:p.Gln1387Hisfs*30) in COL2A1. PCR and
Sanger sequencing using leukocyte-derived DNA from the
proband (IV:3) and his father (III:1) confirmed that both
were heterozygous for the mutation (Fig. 4a). This mutation
has not been reported previously in the Human Genome
Mutation Database or the Exome Aggregation Consortium
database. In addition, it was not present in our in-house
exome database of 165 Thai individuals.
Fig. 1 Pedigree of the index family. The arrow indicates
the proband
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Fig. 3 a Photograph of proband’s father (III: 1) showing disproportionate short stature and barrel-shaped chest. b, c Hand and feet radiographs
are normal without brachydactyly. d Lateral radiograph of the thoracolumbar spine shows platyspondyly with kyphotic deformity. e Pelvis AP
radiograph showing severe hip dysplasia and dislocation. f Thoracolumbar spine and pelvis AP radiographs of the proband’s grandfather also
show platyspondyly and severe hip dysplasia and dislocation
Fig. 2 a Photograph of the proband (IV: 3) showing flattened facial profile, micrognathia, short neck, and short trunk. b Whole spine lateral
radiograph showing oval-shaped vertebral bodies. c Pelvis, femur, and tibial AP radiograph showing retarded ossification of the femoral heads
while other ossification centers are age-appropriate. d Chest radiograph showing age-appropriate ossification centers at humeral heads and
greater tuberosities of humeri. e, f Hand and foot AP radiographs are normal
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Conclusions
Major clinical and radiographic features in our patients
include short stature with platyspondyly, flat midface,
Pierre Robin sequence, hip dysplasia, and retinal detach-
ment. The major extracellular structural protein of these af-
fected organs is collagen type II. This led us to hypothesize
that the etiologic mutation was in COL2A1. WES identified
a five-base pair deletion in this gene. PCR and Sanger se-
quencing confirmed that the proband (IV:3) and his father
(III:1) harbored a heterozygous mutation, c.4161_4165del,
in COL2A1. This out-of-frame deletion is in the C-
propeptide region and is expected to lead to a protein trun-
cation, p.Gln1387Hisfs*30.
Although our patients have a mutation in C-
propeptide region of COL2A1, the phenotype is atypical
for those described for the mutations in C-propeptide
region. Previous reported mutations in the C-propeptide
region of collagen type II lead to one of the six entities:
PLSDT, SPPD, VPED, ANFH, STL1, or early-onset OA.
However, the clinical features of this family are different
from all these six diseases (Table 1).
PLSDT was excluded by absence of wafer-thin platy-
spondyly, small round scapulae, and brachydactyly in
our patients. Moreover, PLSDT patients generally die at
birth [7] but our patients live into adulthood. An im-
portant diagnostic feature of SPPD, brachydactyly [3],
excluded the diagnosis of SPPD. Short stature with pla-
tyspondyly without phalangeal epiphyseal dysplasia ex-
cluded VPED from the diagnosis [4]. ANFH patients
have flattened femoral heads with signs of premature
osteoarthritis. However, the femoral heads of proband’s
father (III:1) and grandfather (II: 3) were totally absent
causing bilateral hip dysplasia and dislocation. Another
important difference is the fact that ANFH patients do
not have short stature, platyspondyly or retinal abnor-
malities [5], while our patients do. Patients with STLI
usually have normal stature and premature OA of many
joints [8, 9], while all our patients (III:1 and II:3) had
short stature (−8 to −9 SD at adulthood). Early-onset
OA patients should present with premature OA of joints
without other skeletal abnormalities, while our patients
had short stature and severe dysplasia of the hips.
STL1 is caused by haploinsufficiency of COL2A1. All
point mutations in COL2A1 leading to STL1 are therefore
expected to be subjected to nonsense-mediated mRNA
decay (NMD). Heterozygous mutations leading to type II
collagenopathies besides STL1 are predicted to have a
dominant negative effect. Previous reports showed that
truncating mutations in the C-propeptide region led either
to STL1 or SPPD, when the mutant RNA did, or did not,
undergo NMD, respectively (Table 2).
Interestingly, our frameshift mutation, expected to cre-
ate a stop codon 69 nucleotides upstream from the exon
53–54 junction, does not lead to STL1. We therefore
hypothesize that the mutant RNA transcribed from the
mutant COL2A1 allele found in our patients may not
undergo NMD; instead that it may produce a mutant
COL2A1 protein that has a dominant negative effect,
interfering with the wild-type COL2A1 and leading to
the unique phenotype. In general, mRNAs harboring a
premature terminal codon (PCT) 50–55 nucleotides up-
stream of the last exon-exon junction are efficiency
degraded [10]. The NMD is signaled by the presence of
the exon junction complex (EJC). However, EJCs are not
Fig. 4 Mutation analysis. a Direct sequencing shows that the proband is heterozygous for a five nucleotide out-of-frame deletion (NM_001844.4:
c.4161_4165del:p.Gln1387His*fs30). b Map of the mutations in the C-propeptide region of COL2A1. Truncating mutations shown above the gene
lead to collagenopathies with short stature, while those shown below the gene lead to disorders with normal stature. The arrowheads points to
the last amino acid residue of the predicted truncated COL2A1. Green: STLI; purple: early-onset OA; red: our mutation; yellow: SPPD; blue: PLSDT.
Numbers correspond to Table 2
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Table 1 Clinical features of type II collagenopathies resulting from mutations in the C-propeptide region of COL2A1, compared with
this family
PLSDT SPPD VPED ANFH STLI Early-onset OA Proband (IV:3) Father (III:1) Grandfather (II:3)
Lethal + - - - - - - - -
Short stature + + - - - N/A + + +
Delayed ossification + + - N/A - N/A +
(hip only)
N/A N/A
Platyspondyly + + - - + N/A + + +
Metaphyseal involvement + + - - - N/A + + N/A
Epiphyseal involvement + + + +
(hip only)
+ N/A + + +
Early onset arthritis N/A + + +
(hip only)
+ + N/A - N/A
Brachydactyly + + + - - N/A - - -
Osteopenia/osteoporosis N/A N/A N/A + + N/A N/A + +
Early onset myopia - + - - + N/A - + N/A
Retinal detachment/tear - + + - + N/A - + N/A
Glaucoma - - - - + N/A - + N/A
Vitreal abnormalities + + + - + N/A - - N/A
Hearing loss - + - - + N/A - - -
Flattened facial profile + + - - + N/A + - -
Pierre-Robin sequence + N/A - - + N/A + - -
Cleft lip/cleft palate/bifid uvula - + - - + N/A + - -
N/A not available, PLSDT platyspondylic lethal skeletal dysplasia, Torrance type, SPPD spondyloperipheral dysplasia, VPED vitreoretinopathy with phalangeal
epiphyseal dysplasia, ANFH avascular necrosis of the femoral head, STL1 Stickler syndrome type I, OA osteoarthritis
Table 2 Truncating mutations in the C-propeptide region of COL2A1
No. Variant location Nucleotide change Predicted protein change Clinical diagnosis Reference
1 Exon 52 c.3906del p.Asn1303Thrfs*9 STL1 Hoornaert et al. [12]
2 Exon 52 c.3891_3898dup p.Ile1300Thrsfs*15 STL1 Hoornaert et al. [12]
3 Intron 52 c.4074 + 1G > T p.Trp1348Cysfs*17 STLI Hoornaert et al. [12]
4 Exon 52 c.3978delC p.Asn1327Ilefs*49 STLI Ahmad et al. [13]
5 Exon 52 c.3957del p.Gly1320Alafs*56 STL1 Annunen et al. [14]
6 Exon 53 c.4088del p.Asp1363Valfs*13 Early-onset OA Barat-Houari et al. [15]
7 Exon 53 c.4161_4165del p.Gln1387Hisfs*30 This report
8 Exon 53 c.4300del p.Leu1434* SPPD Barat-Houari et al. [15]
9 Exon 53 c.4287_4291dup p.Tyr1431Serfs*6 SPPD Zabel et al. [16]
10 Exon 53 c.4314C > A p.Cys1438* SPPD Zankl et al. [3]
11 Exon 54 c.4335G > A p.Trp1445* PLSDT Zankl et al. [2]
12 Exon 54 c.4339A > T p.Lys1447* SPPD Bedeschi et al. [17]
13 Exon 54 c.4332del p.Lys1444Asnfs*27 SPPD Zhang et al. [18]
14 Exon 54 c.4337del p.Gly1446Alafs*25 SPPD Zankl et al. [3]
15 Exon 54 c.4357del p.Arg1453Glyfs*18 SPPD Meredith et al. [19]
16 Exon 54 c.4423C > T p.Gln1475* PLSDT Zankl et al. [2]
17 Exon 54 c.4413_4416del p.Gly1472Profs*9 PLSDT Nishimura et al. [20]
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equally assembled at every exon junction. Therefore, it is
possible that the variation of the EJC may affect NMD
efficiency and lead to efficient degradation of COL2A1
mRNAs harboring a PTC at least 70 nucleotides upstream
of the final exon-exon junction. On the contrary, muta-
tions causing premature stop codons from 69 nucleotides
upstream of the exon 53–54 junction down to the 3’ end
COL2A1 would probably not undergo NMD, have a dom-
inant negative effect, and therefore cause more severe
phenotypes of the spectrum such as SPPD and PLSDT
[2, 3]. Unfortunately, tissues from our patients that
would express COL2A1 are not available to test this hy-
pothesis. Of all the reported mutations in the C-propeptide
region that result in short-stature type II collagenopathies,
our mutation is the farthest truncating mutation from the
C-terminal of COL2A1 (Fig. 4b, Table 2).
Our probands and his father had some different phe-
notypes such as facial profile, eye involvement, and cleft
palate. Intra-and extrafamilial variability of type II col-
lagenopathies has previously been observed in patients
with the same mutation. For instance, in a family with
VPED, a 22-year-old patient had severe premature osteo-
arthritis requiring hip replacement while two older sib-
lings had only mild osteoarthritis [4]. In another family,
while the mosaic mother had SPPD, her fetus suffered
from the lethal PLSDT [11]. These data suggest that
genetic, epigenetic, and environmental modifiers affect
the clinical presentation in type II collagenopathies.
Moreover, these modifiers may be other possible expla-
nations for the atypical phenotype of the patients.
In conclusion, we report an atypical phenotype
resulting from a novel truncating mutation in the C-
propeptide region of COL2A1 with prominent features
including short stature, platyspondyly, hip dysplasia,
and retinal detachment.
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